GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1
Reviewed 21 sourcesPublished by PepVault
Do GLP-1s work after a gastric sleeve or bypass? The trials on regain, the labels' doses side by side, side effects after surgery, and sleeve vs GLP-1 numbers.

- Last reviewed
- Sources
- 21
- Questions
- 7
- Compounds
- 3
The short answer
Yes. In BARI-STEP, the first placebo-controlled trial of semaglutide 2.4 mg after a sleeve or bypass, people whose surgery had worked poorly lost 18.0% of their weight over 68 weeks, against 0.4% on placebo. Clinic records show 12 to 18% on tirzepatide. The trials used the labels' usual step-up. On its own, surgery still takes off more. Your surgical or obesity team decides whether a drug fits, and which.
Evidence: Moderate for semaglutide and liraglutide after surgery (two small placebo-controlled trials of 70 people each, one 68 weeks long); very low for tirzepatide (five observational studies, 6 to 12 months). Sleeve or bypass versus a GLP-1 rests on large records studies, not a finished randomized trial.

Do GLP-1s work after gastric sleeve or bypass surgery?
Yes, and the evidence is now a randomized controlled trial (people assigned to drug or placebo by chance; see pepvault.app/glossary/randomized-controlled-trial), not only clinic records. BARI-STEP, run at University College London, enrolled 70 adults at least a year after a gastric bypass or sleeve gastrectomy who had lost less than 20% of their weight since surgery1. They averaged seven years past surgery, 79% had a sleeve, and mean BMI was 41.51. Everyone got diet advice aiming at a 500-calorie daily deficit; half also got semaglutide 2.4 mg weekly, the Wegovy dose (pepvault.app/drugs/wegovy), and half a placebo, for 68 weeks1.
| At week 68, BARI-STEP1 | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in body weight | −18.0% | +0.4% |
| Lost 10% or more | 85.3% | 6.9% |
| Lost 15% or more | 61.8% | 6.9% |
| Lost 20% or more | 47.1% | 3.4% |
The gap between the arms was 19.2 percentage points, about 21.7 kg1. The same team's earlier trial, BARI-OPTIMISE, gave liraglutide 3.0 mg daily (the Saxenda dose, pepvault.app/drugs/saxenda) to 70 similar patients for 24 weeks: −8.8% against −0.5% on placebo2. In GRAVITAS, liraglutide 1.8 mg lowered HbA1c (the three-month blood sugar average, pepvault.app/glossary/hba1c) by 1.22 points more than placebo in people whose type 2 diabetes stayed or came back after surgery3.
Tirzepatide (Zepbound, Mounjaro) has no placebo-controlled trial after surgery yet. A 2026 systematic review found five observational studies (records of people already treated, without a comparison group chosen by chance; pepvault.app/glossary/observational-study), with 12.0% to 18.1% weight loss at 6 to 12 months, and rated the certainty of the evidence very low5. Pooled clinic studies put semaglutide after surgery at about 9 to 11% and tirzepatide at about 14%67. In one Boston clinic's records, people with a past bypass lost 13.6% at a year on semaglutide, against 10.1% in people with no surgery; a past sleeve made no clear difference16.
PepVault logs each weigh-in, and its weight chart can mark when your protocol started and each dose change, so your team can see what the drug added on top of your surgery. Track your weight in PepVault

How common is weight regain after a sleeve or bypass?
Common. In the PCORnet study of 65,093 US patients, average total weight loss was 31.2% a year after a bypass and 25.2% after a sleeve; at five years it was 25.5% and 18.8%8. After a sleeve, that is about a quarter of the loss given back. A 2025 review puts recurrent weight gain at 15 to 40% of patients after surgery7.
In 2026, 66 international experts agreed on terms for it: "suboptimal" is the preferred word, a response to surgery counts as too small below 10% total weight loss at 12 months, and "recurrent weight gain" means regaining more than 25% of the weight lost, counted from the lowest point9. A GLP-1 drug fits here because GLP-1 is one of the gut's own fullness hormones, and poor weight loss after surgery goes with lower GLP-1 levels in the blood2.
Gastric sleeve vs GLP-1: which takes off more weight?
Surgery, by a wide margin in everyday care, and a narrower one against the best trial results. No finished trial has assigned people to surgery or a drug by chance, so the numbers below come from different studies and are not a head-to-head result10111213.
| Treatment | Where the number comes from | Weight lost |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | STEP 1 trial, 68 weeks, as the Wegovy label reports it12 | 14.9% (placebo 2.4%) |
| Tirzepatide 15 mg (Zepbound) | SURMOUNT-1 trial, 72 weeks, as the Zepbound label reports it13 | 20.9% (placebo 3.1%) |
| Semaglutide, everyday care | Two New York health systems, years 1, 2, 310 | 5.4%, 6.5%, 7.4% |
| Tirzepatide, everyday care | Same study, years 1 and 210 | 9.1%, 10.8% |
| Sleeve gastrectomy | Same study, years 1, 2, 310 | 24.4%, 22.4%, 22.0% |
| Gastric bypass | Same study, years 1, 2, 310 | 29.8%, 28.1%, 28.4% |
Many people stop the drugs in everyday care. Counting only those with a full year of prescriptions, semaglutide reached 7.2% and tirzepatide 11.7% at one year, still well under surgery10. In 45,093 US adults with type 2 diabetes and a BMI of 35 or more, the chance of losing 20% with a normal HbA1c at one year was 3.0% on semaglutide, 13.2% on tirzepatide and 24.0% after a sleeve; the sleeve group was younger and heavier, and had more emergency visits in that year11. A Cleveland Clinic trial is assigning about 140 people to surgery, semaglutide or tirzepatide by chance, with its main results due after July 202714. The two trials: pepvault.app/research/semaglutide-step-1-2021 and pepvault.app/research/tirzepatide-surmount-1-2022.
What dose do people take after surgery?
The same labelled step-up as anyone else. None of the four labels has a separate schedule for people after surgery, and none lists past surgery as a reason not to use the drug12131517. These are the labels' doses, not a dose for any one person (pepvault.app/drugs/ozempic, pepvault.app/drugs/mounjaro, pepvault.app/drugs/zepbound).
| Label | Approved for | Start | Steps | Highest dose |
|---|---|---|---|---|
| Wegovy (semaglutide)12 | Weight; heart risk; MASH | 0.25 mg weekly for 4 weeks | 0.5, 1, 1.7 mg, 4 weeks each; 2.4 mg from week 17 | 7.2 mg, after 4 weeks on 2.4 mg |
| Ozempic (semaglutide)15 | Type 2 diabetes; heart and kidney risk in type 2 diabetes | 0.25 mg weekly for 4 weeks | 0.5 mg, then 1 mg and 2 mg if needed, 4 weeks apart | 2 mg |
| Zepbound (tirzepatide)13 | Weight; sleep apnea | 2.5 mg weekly for 4 weeks | Up 2.5 mg at a time, at least 4 weeks apart; 5, 10 or 15 mg to stay on | 15 mg |
| Mounjaro (tirzepatide)17 | Type 2 diabetes; heart risk in type 2 diabetes | 2.5 mg weekly | Up 2.5 mg at a time, at least 4 weeks apart | 15 mg |
BARI-STEP followed the same 16-week climb to 2.4 mg. Every participant who finished reached 2.4 mg; five of them were then kept on a lower dose (0.5 to 1.7 mg) because of side effects, and a sixth stepped down before leaving the trial1. In an Italian group of 34 people with regain after a bariatric procedure (32 of them surgical), tirzepatide was used at 2.5 to 10 mg a week4. Which drug, how fast to climb and where to stop is set by the prescriber, and the labels allow a slower climb or a lower dose to stay on when a step is hard to tolerate1213. Full schedules: pepvault.app/guides/wegovy-and-ozempic-dosage and pepvault.app/guides/tirzepatide-dosage.
Turn on a dose reminder and PepVault reminds you on your shot day at the time you set, unless the dose is already logged, and each dose you log keeps its amount in your history. Set reminders in PepVault
Does a GLP-1 absorb differently after a sleeve or bypass?
The shots do not depend on the stomach: Wegovy, Ozempic, Zepbound and Mounjaro are injected under the skin and taken up from there into the blood1213. The pills are different. Oral semaglutide (Rybelsus and the Wegovy pill) carries an absorption helper called SNAC that works only in the stomach, where the tablet dissolves18. A 2026 review argues that a smaller stomach, weaker stomach contractions and faster emptying after surgery could lower how much gets in, and suggests the injection until studies measure it; no study has yet measured blood levels of the pill after surgery18. The pill itself is covered in pepvault.app/guides/the-wegovy-pill.
Are the side effects different after surgery?
Mostly the familiar ones. In BARI-STEP the share of people with any side effect was about the same in both arms, 97% on semaglutide and 94% on placebo, with no new safety concern after surgery1. The stomach effects ran higher on the drug, semaglutide against placebo1:
- Nausea: 68.6% against 22.9%.
- Lower appetite: 42.9% against 11.4%.
- Constipation: 37.1% against 22.9%.
- Diarrhea: 60.0% against 40.0%.
- Vomiting: 28.6% against 17.1%.
Two points are specific to surgery. Past bariatric surgery is a risk factor for low blood sugar: in the SELECT heart trial, people with that history had more serious low blood sugar on Wegovy, 2.3% (2 of 87), against none of 97 on placebo12. And in BARI-STEP one person on semaglutide developed restrictive eating, which led to stopping the drug1. Lows after a bypass: pepvault.app/guides/glp-1-low-blood-sugar. Smaller meals, eating slowly and stopping at the first sign of fullness help most in the step-up weeks (more at pepvault.app/peptides/semaglutide/side-effects).
Commonly reported: in patients' own accounts, not trial measures, the old pre-surgery hunger quieting again within the first weeks, and fullness arriving after fewer bites than before the drug.
When to get help Shakiness, sweating, confusion or a fast heartbeat (the label's signs of low blood sugar), or being unable to keep fluids down, is a reason to call your care team that day12.
Drug or revision surgery: who decides?
Your surgical or obesity team, with you. The 2026 expert consensus agreed unanimously that care after surgery is individual and that it is appropriate for specialists to prescribe weight-loss drugs to these patients9. The other option is a second operation (revisional surgery). Weight loss after a revision ranges from 7.8% to 37.7% in the meta-analysis the BARI-STEP authors cite, and they argue 68 weeks of semaglutide may rival it1. In one group of 250 people with regain, those who had a second operation (a sleeve converted to a bypass, or a bypass revised) had lost 17.5% at two years, against 2.8% for those given semaglutide, but that was a records study without safety data for the operations, and its semaglutide result is far below BARI-STEP's191. Going into a revision on a GLP-1 raises the anesthesia question: pepvault.app/guides/glp-1-before-surgery.
Tirzepatide's trials are still coming: a Vanderbilt trial (GRABS) assigned 33 people after a bypass to tirzepatide or usual care by chance, and has posted no results as of November 20, 202621; a placebo-controlled tirzepatide trial in Porto was registered in September 2026 and plans to start in January 202720. And muscle is worth watching: in BARI-STEP, of about 21 kg lost on semaglutide, 15.8 kg was fat and 5.5 kg lean tissue, and the authors call for strength and function testing next1. Protein and strength work are the usual answer (pepvault.app/guides/muscle-on-a-glp-1). Staying on the drug: pepvault.app/guides/keeping-weight-off-after-a-glp-1.
If your surgical dietitian gave you a protein target, type it into the nutrition target in your PepVault profile, and the app tracks each day against your number instead of its own. Track your food in PepVault
Sources
- Stanley C, Mallik R et al. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial (BARI-STEP). Nat Med. 2026;32(7):2662-2672. PubMed 42174253
- Mok J et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158(10):1003-1011. PubMed 37494014
- Miras AD et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549-559. PubMed 31174993
- Vinciguerra F et al. Tirzepatide for recurrent weight gain after bariatric procedures: real-world evidence of efficacy and safety. Obes Surg. 2026;36(7):3697-3704. PubMed 42247124
- Alfuhaydi GL, Alahmed AA, Alfayez OM. Clinical outcomes of tirzepatide after metabolic bariatric surgery: a systematic review. Diabetes Metab Syndr Obes. 2026;19:656297. PubMed 43022657
- Santos-Pereira M, Frutuoso JF et al. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2026;17:1870008. PubMed 42718598
- Osorio Manyari AA et al. Effects of semaglutide and tirzepatide on recurrent weight gain after bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2025;35(12):5596-5605. PubMed 41313431
- Arterburn D et al. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Ann Intern Med. 2018;169(11):741-750. PubMed 30383139
- Wills MV et al. International expert consensus on definitions and management of weight recurrence and suboptimal response after metabolic and bariatric surgery: a Delphi study. Surg Obes Relat Dis. 2026;22(7):753-761. PubMed 41963214
- Brown A et al. Real-world effectiveness of semaglutide and tirzepatide compared with bariatric surgery. Obesity (Silver Spring). 2026;34(8):1583-1591. PubMed 42345739
- Leslie DB et al. 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 2026;14(8):638-648. PubMed 42309121
- Wegovy (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, June 30, 2026 (SPL version 19). dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, September 2, 2026 (SPL version 40). dailymed.nlm.nih.gov
- ClinicalTrials.gov. NCT06803888: Efficacy and safety of bariatric surgery, semaglutide once weekly, and tirzepatide once weekly in patients with obesity (sponsor Ali Aminian, Cleveland Clinic). Active, not recruiting; primary completion estimated July 2027 (record updated September 2026). clinicaltrials.gov
- Ozempic (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, June 10, 2026 (SPL version 20). dailymed.nlm.nih.gov
- Medhati P et al. GLP-1RA in the real world: 1-year compliance and outcomes of semaglutide use in patients with or without previous history of bariatric surgery. Ann Surg. 2025. PubMed 40334053
- Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, September 2, 2026 (SPL version 40). dailymed.nlm.nih.gov
- Dahan AE, Azran C, Dahan A. Is oral semaglutide a good fit for patients after metabolic bariatric surgery? A biopharmaceutical mechanistic perspective. Pharmaceutics. 2026;18(4):466. PubMed 42076118
- Rivero-Moreno Y et al. Revisional metabolic and bariatric surgery versus semaglutide: which strategy has greater efficacy for recurrent weight gain after primary bariatric surgery? Obes Surg. 2026;36(5):2361-2371. PubMed 41906069
- ClinicalTrials.gov. NCT07829198 (TirBaS): Efficacy of tirzepatide for weight management in patients with suboptimal weight loss after bariatric surgery, a randomized, double-blind, placebo-controlled trial (sponsor Universidade do Porto). Not yet recruiting; first posted September 18, 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT06162715: GLP-1 receptor agonists post-bariatric surgery (GRABS) pilot trial (sponsor Vanderbilt University Medical Center). Randomized, open-label, 33 enrolled; primary completion October 10, 2026; no results posted (record updated November 18, 2026). clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.